LEADER 01280nam  2200373Ia 450 
001 9910697070803321
005 20230902162200.0
035   $a(CKB)5470000002384192
035   $a(OCoLC)605914286
035   $a(EXLCZ)995470000002384192
100   $a20100409d1998      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eacute or chronic bacterial prostatitis, developing antimicrobial drugs for treatment
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[1998]
215   $a1 online resource (i, 12 pages)
300   $a"Draft guidance."
300   $a"Clin-anti."
300   $a"July 1998."
517   $aGuidance for industry 
606   $aProstatitis$xTreatment$zUnited States
606   $aAnti-infective agents$zUnited States
615  0$aProstatitis$xTreatment
615  0$aAnti-infective agents
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910697070803321
996   $aGuidance for industry$93434577
997   $aUNINA